Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

PubWeight™: 0.82‹?›

🔗 View Article (PMC 4187119)

Published in Physiol Genomics on August 05, 2014

Authors

Tim N Beck1, Adaeze J Chikwem2, Nehal R Solanki3, Erica A Golemis4

Author Affiliations

1: Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Program in Molecular and Cell Biology and Genetics, Drexel University College of Medicine, Philadelphia, Pennsylvania; and.
2: Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Temple University School of Medicine, Philadelphia, Pennsylvania; and.
3: Immune Cell Development and Host Defense Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Program in Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania.
4: Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Temple University School of Medicine, Philadelphia, Pennsylvania; and Program in Molecular and Cell Biology and Genetics, Drexel University College of Medicine, Philadelphia, Pennsylvania; and Erica.Golemis@fccc.edu.

Articles cited by this

(truncated to the top 100)

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46

Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19

Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res (2003) 103.76

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59

The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56

From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res (2006) 44.35

Integrative genomics viewer. Nat Biotechnol (2011) 42.83

Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78

Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99

Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68

The Pfam protein families database. Nucleic Acids Res (2011) 33.46

The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78

KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res (2011) 30.20

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

GenePattern 2.0. Nat Genet (2006) 29.07

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98

Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55

Cancer genome landscapes. Science (2013) 25.33

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58

Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94

Human Protein Reference Database--2009 update. Nucleic Acids Res (2008) 21.25

The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol (2000) 21.15

Drug development: Raise standards for preclinical cancer research. Nature (2012) 20.64

International network of cancer genome projects. Nature (2010) 20.35

Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54

Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13

Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53

Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 18.31

STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res (2012) 18.26

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67

TGFbeta in Cancer. Cell (2008) 17.44

Announcing the worldwide Protein Data Bank. Nat Struct Biol (2003) 17.06

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94

Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91

NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res (2012) 15.84

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01

Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91

Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17

A perspective on cancer cell metastasis. Science (2011) 13.31

Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest (2003) 12.56

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16

Clonal evolution in cancer. Nature (2012) 11.07

GenBank. Nucleic Acids Res (2012) 10.89

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87

Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83

Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74

STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res (2005) 10.44

Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15

The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J (1989) 10.05

Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04

Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66

EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27

Biomarkers for epithelial-mesenchymal transitions. J Clin Invest (2009) 8.76

A module map showing conditional activity of expression modules in cancer. Nat Genet (2004) 8.57

The Reactome pathway knowledgebase. Nucleic Acids Res (2013) 8.56

Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med (2011) 8.48

Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37

Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36

TGFβ signalling in context. Nat Rev Mol Cell Biol (2012) 8.08

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97

Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol (2011) 7.84

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73

The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57

Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol (2008) 7.37

Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res (2008) 6.95

Systematic discovery of in vivo phosphorylation networks. Cell (2007) 6.94

Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther (2012) 6.92

miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67

Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43

Cancer invasion and the microenvironment: plasticity and reciprocity. Cell (2011) 6.36

Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell (2011) 6.21

Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09

Pathguide: a pathway resource list. Nucleic Acids Res (2006) 6.05

Rac activation and inactivation control plasticity of tumor cell movement. Cell (2008) 6.01

Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell (2008) 5.88

Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell (2001) 5.84

Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47

Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44

Database resources of the National Center for Biotechnology Information. Nucleic Acids Res (2013) 5.25

Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol (2002) 5.02

ArrayExpress update--trends in database growth and links to data analysis tools. Nucleic Acids Res (2012) 4.91

Automated high-dimensional flow cytometric data analysis. Proc Natl Acad Sci U S A (2009) 4.91

Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79

Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76

Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68

LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell (2013) 4.58